The development of effective and safe COVID‐19 vaccines is a major move forward in our
global effort to control the SARS‐CoV‐2 pandemic. The aims of this study were (1) to …

Objective To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg
doses of the BIV1-CovIran vaccine. Design Randomised, placebo controlled, double blind …

After about 2 years since severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2),
first infections were detected in Wuhan city of China in December 2019, which was followed …

Background The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine
candidates. We aimed to assess the safety and immunogenicity of an inactivated severe …

The rapid spread of SARS-CoV-2 with its mutating strains has posed a global threat to safety
during this COVID-19 pandemic. Thus far, there are 123 candidate vaccines in human …

Objective Assessing safety and immunogenicity of an inactivated whole virus particle
vaccine. Design Single-centre, double-blind, randomised, placebo-controlled, phase I (stage …

Since the emergence of SARS-CoV-2 at the end of 2019, 64 candidate vaccines are in
clinical development and 173 are in the pre-clinical phase. Five types of vaccines are …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging viral
zoonotic illness that has developed a distinctive and threatening situation globally …

The COVID-19 pandemic is a global health crisis that poses a great challenge to the public
health system of affected countries. Safe and effective vaccines are needed to overcome this …

Summary The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The …